Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inhibikase Therapeutics stock

Own Inhibikase Therapeutics stock in just a few minutes.

Inhibikase Therapeutics, Inc is a biotechnology business based in the US. Inhibikase Therapeutics shares (IKT) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibikase Therapeutics employs 3 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Inhibikase Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IKT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Inhibikase Therapeutics share price

Use our graph to track the performance of IKT stocks over time.

Inhibikase Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$5.00 - $11.80
50-day moving average $5.75
200-day moving average $6.61
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Inhibikase Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inhibikase Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inhibikase Therapeutics financials

Revenue TTM $698,468
Gross profit TTM $-195,334
Return on assets TTM -23.77%
Return on equity TTM -107.58%
Profit margin 0%
Book value N/A
Market capitalisation $52.8 million

TTM: trailing 12 months

Shorting Inhibikase Therapeutics shares

There are currently 72,193 Inhibikase Therapeutics shares held short by investors – that's known as Inhibikase Therapeutics's "short interest". This figure is 14.1% down from 84,031 last month.

There are a few different ways that this level of interest in shorting Inhibikase Therapeutics shares can be evaluated.

Inhibikase Therapeutics's "short interest ratio" (SIR)

Inhibikase Therapeutics's "short interest ratio" (SIR) is the quantity of Inhibikase Therapeutics shares currently shorted divided by the average quantity of Inhibikase Therapeutics shares traded daily (recently around 34542.105263158). Inhibikase Therapeutics's SIR currently stands at 2.09. In other words for every 100,000 Inhibikase Therapeutics shares traded daily on the market, roughly 2090 shares are currently held short.

To gain some more context, you can compare Inhibikase Therapeutics's short interest ratio against those of similar companies.

However Inhibikase Therapeutics's short interest can also be evaluated against the total number of Inhibikase Therapeutics shares, or, against the total number of tradable Inhibikase Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibikase Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inhibikase Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0152% of the tradable shares (for every 100,000 tradable Inhibikase Therapeutics shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inhibikase Therapeutics.

Find out more about how you can short Inhibikase Therapeutics stock.

Inhibikase Therapeutics share dividends

We're not expecting Inhibikase Therapeutics to pay a dividend over the next 12 months.

Inhibikase Therapeutics overview

Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site